Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887.HK) has officially listed on the main board of the Hong Kong Stock Exchange following its absorption and merger with Dongyang Sunshine Changjiang Pharmaceutical, aiming to become a benchmark innovative pharmaceutical company with global influence by leveraging its deep R&D foundation and comprehensive international layout [1] Group 1 - The merger creates an integrated closed loop of research, production, and sales, enhancing operational efficiency [1] - The company is driven by a dual engine of "innovation + internationalization," focusing on developing high-potential blockbuster products [1] - The strategy includes accelerating commercialization processes and promoting overseas transactions to deepen its presence in the Chinese market [1]